NCT05169697已完成1 期
A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 9
- 主要终点
- Determined the recommended Phase II dose (RP2D)
研究概览
简要总结
A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible for study entry patients must satisfy all of the following criteria:
- •Subjects must have the ability to understand and willingness to sign a written informed consent document.
- •Subjects must have histologically advanced or cytologically confirmed solid tumor and and must have at least 1 unidimensional measurable lesion by RECIST 1.
- •Subjects have progressed on after treatment with at least one standard therapy, or intolerant of the standard therapy, or no standard therapy accessible to the patients due to any reason.
- •Subjects must be age 18 to 80 years of age at the time of screening.
- •Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy ≥3 months based on investigator's judgement.
- •Subjects have adequate bone marrow and other organ function at the screening visit.
- •Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test within 7 days of the first dosing. Women of reproductive potential are those who have not been post-menopausal for at least 12 months or who have not undergone bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy.
排除标准
- •Subjects who meet any of the following criteria cannot be enrolled:
- •Subjects have another active invasive malignancy within 5 years.
- •Previous exposure to TNFR such as anti-OX40 antibodies.
- •Subjects must not have received any anticancer therapy or another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of the study treatment(subject to the longer one).
- •Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ Grade 1 per CTCAE 5.0, except alopecia ≤ Grade
- •Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.
- •Subjects must not have a known or suspected history of an autoimmune disorder, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment.
- •Clinically uncontrolled intercurrent illness, including but not limit to an ongoing active infection, active coagulopathy, uncontrolled diabetes (blood glucose > 250 mg/dl), uncontrolled pleural and peritoneal effusion, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies
- •Subjects must not have active infection of human immunodeficiency virus, hepatitis B, hepatitis C or Covid-19.
研究组 & 干预措施
YH002 in combination with YH001
Experimental
Dose escalation:A traditional 3+3 dose escalation algorithm will be utilized to identify MTD and/or RP2D Dose expansion:One selected dose after the escalation stage will be expanded to enroll additional 20 subjects. The subjects will be divided into two groups：A and B.
干预措施: YH002+YH001 (Drug)
结局指标
主要结局
Determined the recommended Phase II dose (RP2D)
时间窗: Up to 1 year after the last dosing
The safety profile of combination treatment will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0
Determined the maximum tolerated dose (MTD)
时间窗: Up to 1 year after the last dosing
The safety profile of combination treatment will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
1 期
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung CancerNCT05347628Avistone Biotechnology Co., Ltd.91
已完成
1 期
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsSolid TumorNCT01363024Genentech, Inc.24
已完成
1 期
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLAML/MDSRelapseRefractory Acute Lymphoblastic LeukemiaRelapse LeukemiaRelapsed Adult AMLCMMLNCT04139434Newave Pharmaceutical Inc32
终止
1 期
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung CancerNSCLC Stage IVNSCLC Stage IIIBAdvanced Non-Small Cell Squamous Lung CancerAdvanced Non-Small Cell Lung CancerAdvanced Non-Small Cell Non-Squamous Lung CancerNon-Small Cell Lung CancerNSCLCNCT05652868Mythic Therapeutics227
进行中（未招募）
1 期
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesAdvanced Hematologic MalignancyRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaNCT04891757Foghorn Therapeutics Inc.144